Which has better valuation & earnings, NTRA or GILD?

Gilead Sciences has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 20.51 -$208.16M -$1.36 N/A Gilead Sciences $29.44B 6.36 $8.51B -$2.67 N/A

Is NTRA or GILD more profitable?

Natera has a net margin of -7.11% compared to Gilead Sciences' net margin of -10.64%. Gilead Sciences' return on equity of -2.11% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.38% -7.87% Gilead Sciences -10.64% -2.11% -0.75%

Does the media prefer NTRA or GILD?

In the previous week, Gilead Sciences had 26 more articles in the media than Natera. MarketBeat recorded 55 mentions for Gilead Sciences and 29 mentions for Natera. Gilead Sciences' average media sentiment score of 1.23 beat Natera's score of 1.10 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 24 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 36 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor VRTX or NTRA?

In the previous week, Natera had 2 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 29 mentions for Natera and 27 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.38 beat Natera's score of 1.10 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 22 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Natera 24 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer REGN or NTRA?

In the previous week, Regeneron Pharmaceuticals had 22 more articles in the media than Natera. MarketBeat recorded 51 mentions for Regeneron Pharmaceuticals and 29 mentions for Natera. Natera's average media sentiment score of 1.10 beat Regeneron Pharmaceuticals' score of 0.66 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 24 Very Positive mention(s) 3 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Natera 24 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ARGX or NTRA?

argenex has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 15.21 $1.29B $26.04 39.68 Natera $2.31B 20.51 -$208.16M -$1.36 N/A

Is ARGX or NTRA more profitable?

argenex has a net margin of 32.19% compared to Natera's net margin of -7.11%. argenex's return on equity of 43.59% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 43.59% 36.66% Natera -7.11% -11.38% -7.87%

Does the media favor ARGX or NTRA?

In the previous week, Natera had 13 more articles in the media than argenex. MarketBeat recorded 29 mentions for Natera and 16 mentions for argenex. Natera's average media sentiment score of 1.10 beat argenex's score of 0.51 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 3 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 24 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, NTRA or MRNA?

Natera has higher revenue and earnings than Moderna. Natera is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 20.51 -$208.16M -$1.36 N/A Moderna $1.94B 29.89 -$2.82B -$7.99 N/A

Is NTRA or MRNA more profitable?

Natera has a net margin of -7.11% compared to Moderna's net margin of -141.43%. Natera's return on equity of -11.38% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.38% -7.87% Moderna -141.43% -28.30% -19.39%

Does the media refer more to NTRA or MRNA?

In the previous week, Moderna had 46 more articles in the media than Natera. MarketBeat recorded 75 mentions for Moderna and 29 mentions for Natera. Natera's average media sentiment score of 1.10 beat Moderna's score of 0.53 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 24 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 29 Very Positive mention(s) 17 Positive mention(s) 12 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Positive

Natera (NTRA) Competitors

$328.18 +0.51 (+0.16%)

As of 04:00 PM Eastern

Compare

NTRA vs. GILD, VRTX, REGN, ARGX, and MRNA

Should you buy Natera stock or one of its competitors? Natera's main competitors and comparable companies include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), argenex (ARGX), and Moderna (MRNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Natera compare to Gilead Sciences?

Natera (NASDAQ:NTRA) and Gilead Sciences (NASDAQ:GILD) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Natera has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

Natera currently has a consensus target price of $319.38, suggesting a potential downside of 2.68%. Gilead Sciences has a consensus target price of $158.04, suggesting a potential upside of 4.67%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.87

Gilead Sciences has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.51	-$208.16M	-$1.36	N/A
Gilead Sciences	$29.44B	6.36	$8.51B	-$2.67	N/A

99.9% of Natera shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 5.1% of Natera shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Natera has a net margin of -7.11% compared to Gilead Sciences' net margin of -10.64%. Gilead Sciences' return on equity of -2.11% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Gilead Sciences	-10.64%	-2.11%	-0.75%

In the previous week, Gilead Sciences had 26 more articles in the media than Natera. MarketBeat recorded 55 mentions for Gilead Sciences and 29 mentions for Natera. Gilead Sciences' average media sentiment score of 1.23 beat Natera's score of 1.10 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	24 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	36 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Gilead Sciences beats Natera on 10 of the 17 factors compared between the two stocks.

How does Natera compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Vertex Pharmaceuticals has a net margin of 35.00% compared to Natera's net margin of -7.11%. Vertex Pharmaceuticals' return on equity of 23.09% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.00%	23.09%	16.72%
Natera	-7.11%	-11.38%	-7.87%

In the previous week, Natera had 2 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 29 mentions for Natera and 27 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.38 beat Natera's score of 1.10 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	22 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	24 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	11.55	$3.95B	$17.18	31.79
Natera	$2.31B	20.51	-$208.16M	-$1.36	N/A

Vertex Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Natera has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Natera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Vertex Pharmaceuticals presently has a consensus price target of $569.52, suggesting a potential upside of 4.29%. Natera has a consensus price target of $319.38, suggesting a potential downside of 2.68%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Vertex Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

Vertex Pharmaceuticals beats Natera on 11 of the 17 factors compared between the two stocks.

How does Natera compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Natera's net margin of -7.11%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Natera	-7.11%	-11.38%	-7.87%

Regeneron Pharmaceuticals presently has a consensus price target of $800.36, suggesting a potential downside of 3.31%. Natera has a consensus price target of $319.38, suggesting a potential downside of 2.68%. Given Natera's stronger consensus rating and higher probable upside, analysts plainly believe Natera is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Regeneron Pharmaceuticals had 22 more articles in the media than Natera. MarketBeat recorded 51 mentions for Regeneron Pharmaceuticals and 29 mentions for Natera. Natera's average media sentiment score of 1.10 beat Regeneron Pharmaceuticals' score of 0.66 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	24 Very Positive mention(s)	3 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Natera	24 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, Natera has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.94	$4.50B	$40.46	20.46
Natera	$2.31B	20.51	-$208.16M	-$1.36	N/A

Summary

Regeneron Pharmaceuticals beats Natera on 9 of the 17 factors compared between the two stocks.

How does Natera compare to argenex?

argenex (NASDAQ:ARGX) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

argenex currently has a consensus target price of $1,158.61, suggesting a potential upside of 12.14%. Natera has a consensus target price of $319.38, suggesting a potential downside of 2.68%. Given argenex's stronger consensus rating and higher possible upside, equities research analysts clearly believe argenex is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

60.3% of argenex shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 2.4% of argenex shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

argenex has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	15.21	$1.29B	$26.04	39.68
Natera	$2.31B	20.51	-$208.16M	-$1.36	N/A

argenex has a net margin of 32.19% compared to Natera's net margin of -7.11%. argenex's return on equity of 43.59% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Natera	-7.11%	-11.38%	-7.87%

In the previous week, Natera had 13 more articles in the media than argenex. MarketBeat recorded 29 mentions for Natera and 16 mentions for argenex. Natera's average media sentiment score of 1.10 beat argenex's score of 0.51 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	3 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	24 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Natera has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

Summary

argenex beats Natera on 10 of the 16 factors compared between the two stocks.

How does Natera compare to Moderna?

Natera (NASDAQ:NTRA) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Natera currently has a consensus price target of $319.38, indicating a potential downside of 2.68%. Moderna has a consensus price target of $76.72, indicating a potential downside of 47.29%. Given Natera's stronger consensus rating and higher possible upside, equities analysts plainly believe Natera is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

In the previous week, Moderna had 46 more articles in the media than Natera. MarketBeat recorded 75 mentions for Moderna and 29 mentions for Natera. Natera's average media sentiment score of 1.10 beat Moderna's score of 0.53 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	24 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	29 Very Positive mention(s)	17 Positive mention(s)	12 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Positive

Natera has a net margin of -7.11% compared to Moderna's net margin of -141.43%. Natera's return on equity of -11.38% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Moderna	-141.43%	-28.30%	-19.39%

Natera has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Comparatively, Moderna has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Natera has higher revenue and earnings than Moderna. Natera is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.51	-$208.16M	-$1.36	N/A
Moderna	$1.94B	29.89	-$2.82B	-$7.99	N/A

99.9% of Natera shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 5.1% of Natera shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Natera beats Moderna on 13 of the 17 factors compared between the two stocks.

Get Natera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTRA vs. The Competition

Export

Metric	Natera	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$47.23B	$4.03B	$7.28B	$12.92B
Dividend Yield	N/A	3.60%	2.53%	8.90%
P/E Ratio	-241.31	12.65	272.42	25.42
Price / Sales	20.51	1,342.84	623.39	95.06
Price / Cash	N/A	107.40	77.39	52.28
Price / Book	25.96	16.15	12.85	6.17
Net Income	-$208.16M	-$22.76M	$3.47B	$349.50M
7 Day Performance	0.59%	1.13%	1.24%	-0.05%
1 Month Performance	19.26%	8.93%	5.81%	0.80%
1 Year Performance	97.03%	52.96%	25.75%	15.62%

Natera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTRA Natera	2.4773 of 5 stars	$328.18 +0.2%	$319.38 -2.7%	+95.6%	$47.23B	$2.31B	N/A	6,140	Positive News Insider Trade
GILD Gilead Sciences	3.7168 of 5 stars	$146.34 +0.5%	$158.04 +8.0%	+33.8%	$180.64B	$29.44B	N/A	17,000	Trending News Insider Trade Analyst Revision
VRTX Vertex Pharmaceuticals	3.6104 of 5 stars	$544.52 +0.5%	$563.50 +3.5%	+40.7%	$137.48B	$12.00B	31.69	6,400	Positive News Analyst Forecast
REGN Regeneron Pharmaceuticals	4.0684 of 5 stars	$799.08 +0.6%	$800.36 +0.2%	+49.6%	$81.77B	$14.34B	19.75	15,410	Trending News Insider Trade
ARGX argenex	4.2691 of 5 stars	$1,031.66 +0.8%	$1,158.61 +12.3%	+45.9%	$64.01B	$4.25B	39.62	1,863	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTRA) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Natera (NTRA) Competitors

NTRA vs. GILD, VRTX, REGN, ARGX, and MRNA

How does Natera compare to Gilead Sciences?

Summary

How does Natera compare to Vertex Pharmaceuticals?

Summary

How does Natera compare to Regeneron Pharmaceuticals?

Summary

How does Natera compare to argenex?

Summary

How does Natera compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRA vs. The Competition

Natera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Natera (NTRA) Competitors

NTRA vs. GILD, VRTX, REGN, ARGX, and MRNA

How does Natera compare to Gilead Sciences?

Which has more volatility & risk, NTRA or GILD?

Do analysts recommend NTRA or GILD?

Which has better valuation & earnings, NTRA or GILD?

Do insiders & institutionals hold more shares of NTRA or GILD?

Is NTRA or GILD more profitable?

Does the media prefer NTRA or GILD?

Summary

How does Natera compare to Vertex Pharmaceuticals?

Is VRTX or NTRA more profitable?

Does the media favor VRTX or NTRA?

Which has better valuation & earnings, VRTX or NTRA?

Which has more volatility and risk, VRTX or NTRA?

Do insiders and institutionals hold more shares of VRTX or NTRA?

Do analysts prefer VRTX or NTRA?

Summary

How does Natera compare to Regeneron Pharmaceuticals?

Is REGN or NTRA more profitable?

Do analysts prefer REGN or NTRA?

Does the media prefer REGN or NTRA?

Which has more volatility & risk, REGN or NTRA?

Do institutionals and insiders hold more shares of REGN or NTRA?

Which has better earnings & valuation, REGN or NTRA?

Summary

How does Natera compare to argenex?

Do analysts prefer ARGX or NTRA?

Do institutionals & insiders hold more shares of ARGX or NTRA?

Which has higher valuation & earnings, ARGX or NTRA?

Is ARGX or NTRA more profitable?

Does the media favor ARGX or NTRA?

Which has more volatility and risk, ARGX or NTRA?

Summary

How does Natera compare to Moderna?

Do analysts recommend NTRA or MRNA?

Does the media refer more to NTRA or MRNA?

Is NTRA or MRNA more profitable?

Which has more volatility & risk, NTRA or MRNA?

Which has higher valuation and earnings, NTRA or MRNA?

Do institutionals & insiders believe in NTRA or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRA vs. The Competition

Natera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools